Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 3/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29397749 | 0.76 | CASR (0.44) | CASR | |
| SCHEMBL31429684 | 0.74 | GFPT1 (0.36) | GFPT1CASRITGB3ITGA2B | |
| SCHEMBL25345631 | 0.72 | GFPT1 (0.52) | GFPT1CASRGRIK1SLC7A5 | |
| SCHEMBL542281 | 0.72 | GFPT1 (0.52) | GFPT1CASRGRIK1SLC7A5 | |
| SCHEMBL542282 | 0.72 | GFPT1 (0.52) | GFPT1CASRGRIK1SLC7A5 | |
| SCHEMBL1769506 | 0.69 | ITGB3 (0.50) | GFPT1ITGB3ITGA2B | |
| SCHEMBL1769508 | 0.69 | ITGB3 (0.50) | GFPT1ITGB3ITGA2B | |
| SCHEMBL8234598 | 0.69 | GFPT1 (0.39) | GFPT1CASRITGB3ITGA2B | |
| SCHEMBL2716862 | 0.69 | GFPT1 (0.49) | GFPT1CASRGRIK1SLC7A5 | |
| SCHEMBL10280376 | 0.69 | GFPT1 (0.49) | GFPT1CASRGRIK1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025027659-A1 | PEPTIDE MIMETIC CONJUGATED 3D POROUS POLYMER SCAFFOLD | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2025-02-06 | — | — | WO | claimed |
| WO-2025010117-A1 | INFLUENZA B HEADLESS HA UNIVERSAL VACCINES | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2025-01-09 | — | — | WO | claimed |
| CN-117926235-A | Halogen-free high-stability chemical palladium plating bath | 江苏矽智半导体科技有限公司 | 2024-04-26 | — | — | CN | claimed |
| WO-2023179890-A1 | CALCULATING APPLICATION SERVICE ENERGY CONSUMPTION IN A WIRELESS COMMUNICATION NETWORK | LENOVO (SINGAPORE) PTE. LTD (SG) | 2023-09-28 | — | — | WO | claimed |
| US-12612456-B2 | CD19 antibodies and methods of using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260108622-A1 | NON-PEGYLATED LIPID NANOPARTICLES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-04-23 | — | — | US | disclosed |
| US-12582710-B2 | Single-chain coronavirus viral membrane protein complexes | UNIVERSITY OF HOUSTON SYSTEM (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260042860-A1 | ANTI-CD24 ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260015435-A1 | ANTI-POLYSIALIC ACID ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260002195-A1 | METHOD FOR ANALYZING BLOOD STORED FOR LATER ANALYSIS OF CELL FREE DNA | YOURGENE HEALTH CANADA INC. (CA) | 2026-01-01 | — | — | US | disclosed |
| US-12507900-B2 | Pressure based structural heart assessment systems and methods | OPSENS, INC. (CA) | 2025-12-30 | — | — | US | disclosed |
| US-12509515-B2 | CD22 antibodies and methods of using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-12-30 | — | — | US | disclosed |
| EP-3976659-A1 | ANTI-GLYPICAN-3 ANTIBODIES AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20220098329-A1 | HETERODIMERIC TETRAVALENCY AND SPECIFICITY ANTIBODY COMPOSITIONS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220090034-A1 | COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS | SOLIS BIODYNE OÜ (EE) | 2022-03-24 | — | — | US | disclosed |
| EP-3968851-A1 | PRESSURE BASED STRUCTURAL HEART ASSESSMENT SYSTEMS AND METHODS | Opsens Inc. (CA) | 2022-03-23 | — | — | EP | disclosed |
| WO-2022047176-A2 | SINGLE-CHAIN CORONAVIRUS VIRAL MEMBRANE PROTEIN COMPLEXES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2022-03-03 | — | — | WO | disclosed |
| CN-109342743-B | Preparation method of denatured IgG capable of being efficiently combined with rheumatoid factor | 菲鹏生物股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-3953385-A1 | CD19 ANTIBODIES AND METHODS OF USING THE SAME | Memorial Sloan Kettering Cancer Center (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2022032003-A2 | ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOF | ABPRO CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582710-B2 | Single-chain coronavirus viral membrane protein complexes | SARS1, MAX, TMPRSS2 | GFPT1 1654/4885CASR 1746/4885GRIK1 3758/4885 |
| US-20260042860-A1 | ANTI-CD24 ANTIBODIES AND USES THEREOF | CD22, FCGR2A, CD2BP2 | GFPT1 3990/4885CASR 2960/4885GRIK1 4818/4885 |
| US-20260108622-A1 | NON-PEGYLATED LIPID NANOPARTICLES | CD44, ASGR1, PLTP | GFPT1 524/4885CASR 1414/4885GRIK1 1507/4885 |
| US-12612456-B2 | CD19 antibodies and methods of using the same | CD74, CD4, CD2 | GFPT1 4326/4885CASR 2920/4885GRIK1 2165/4885 |
| US-20260015435-A1 | ANTI-POLYSIALIC ACID ANTIBODIES AND USES THEREOF | VSIG8, CD74, FCGR2A | GFPT1 4377/4885CASR 3982/4885GRIK1 1640/4885 |
| US-12509515-B2 | CD22 antibodies and methods of using the same | CD74, CD22, CD2 | GFPT1 4480/4885CASR 2346/4885GRIK1 2082/4885 |
| US-12507900-B2 | Pressure based structural heart assessment systems and methods | NOTCH2, NOTCH1, NOTCH4 | GFPT1 1721/4885CASR 56/4885GRIK1 4100/4885 |
| US-20260002195-A1 | METHOD FOR ANALYZING BLOOD STORED FOR LATER ANALYSIS OF CELL FREE DNA | BRCA1, CASK, ALPP | GFPT1 3710/4885CASR 671/4885GRIK1 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.